Redhill Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.10.17	RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (GlobeNewswire)
02.10.17	RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn's Disease with Top-Line Results Expected Mid-2018 (GlobeNewswire)
18.09.17	Keep An Eye On These Biotech Stocks This Month, If Invested (RTTNews)
13.09.17	RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S. (GlobeNewswire)
17.08.17	RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules (GlobeNewswire)
10.08.17	RedHill Biopharma Provides 2017 Semi-Annual Business Update (GlobeNewswire)
31.07.17	RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease (GlobeNewswire)
25.07.17	RedHill Biopharma Reports 2017 Second Quarter Financial Results (GlobeNewswire)
17.07.17	RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D (GlobeNewswire)
12.07.17	RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease (GlobeNewswire)
21.12.16	RedHill Biopharma gibt beabsichtigtes gleichzeitiges öffentliches und registriertes direktes Zeichnungsangebot seiner American Depositary Shares und Optionsscheine bekannt (GlobeNewswire)
20.12.16	RedHill Biopharma Announces Proposed Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants (GlobeNewswire)
19.12.16	RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma (GlobeNewswire)
14.11.16	RedHill Biopharma Reports 2016 Third Quarter Financial Results (GlobeNewswire)
10.11.16	RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study (GlobeNewswire)
03.11.16	RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA® and Expected Timing of Top-Line Results (GlobeNewswire)
02.11.16	RedHill Biopharma Announces Withdrawal of Public Offering of its American Depositary Shares (GlobeNewswire)
01.11.16	RedHill Biopharma to Host Investor Conference Call Today at 18:00 EDT Following Announcement of Proposed Public Offering of its American Depository Shares (GlobeNewswire)
01.11.16	RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares (GlobeNewswire)
06.10.16	RedHill Biopharma to Host Webcast Today at 8:30 am EDT Following Announcement of Progress Update on RHB-104 Phase III Crohn's Disease Program Including the Introduction of an Option for Early Stop ... (GlobeNewswire)
06.10.16	RedHill Biopharma Provides Progress Update on RHB-104 Phase III Crohn's Disease Program and Introduces Option for Early Stop... (GlobeNewswire)
05.10.16	RedHill Biopharma Announces Initiation of Phase II Study with YELIVA(TM) in Hepatocellular Carcinoma at the Medical University of South Carolina (GlobeNewswire)
21.09.16	RedHill Biopharma and IntelGenx Announce RIZAPORT® Commercialization Term Sheet with Pharmatronic Co. for Korea (GlobeNewswire)
12.09.16	RedHill Biopharma Announces Research Collaboration with Stanford University for YELIVA(TM) (GlobeNewswire)
08.09.16	RedHill Biopharma Announces Phase Ib/II Study with YELIVA(TM) Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center (GlobeNewswire)
29.08.16	RedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis (GlobeNewswire)
11.08.16	RedHill Biopharma Provides 2016 Semi-Annual R&D Update (GlobeNewswire)
01.08.16	RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis (GlobeNewswire)
26.07.16	RedHill Biopharma Reports 2016 Second Quarter Financial Results (GlobeNewswire)
21.07.16	RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection (GlobeNewswire)
13.07.16	RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment (GlobeNewswire)
05.07.16	RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT(TM) for... (GlobeNewswire)
22.06.16	RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection (GlobeNewswire)
22.06.16	Keep An Eye On Nicox, OPK Gets FDA Nod, PBMD Abuzz, RDHL On The Move (RTTNews)
21.06.16	RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors (GlobeNewswire)
04.05.16	RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study (GlobeNewswire)
18.04.16	RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection (GlobeNewswire)
11.04.16	RedHill Biopharma Initiates Phase II Study of BEKINDA(TM) for Irritable Bowel Syndrome (GlobeNewswire)
31.03.16	RedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis (GlobeNewswire)
29.03.16	RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories (GlobeNewswire)
08.03.16	RedHill Biopharma Reports Successful Final Results of Phase III Study With RHB-105 for H. pylori Infection (GlobeNewswire)
08.02.16	RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute for Oncology Drug RP101 (GlobeNewswire)
09.11.15	RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines (GlobeNewswire)
01.07.15	RedHill Gets Two Notices Of Allowance From USPTO Regarding RHB-104 (RTTNews)
17.06.15	ANTH Awaits Lupus Study Data, FDA Nod For IPXL, TNXP To Report Trial Data In Q4 (RTTNews)
15.06.15	RedHill Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori (RTTNews)
01.12.14	RedHill Biopharma: BfArM Validates European MAA Submitted For RIZAPORT (RTTNews)
03.03.14	RedHill Biopharma And IntelGenx Submit Response To FDA CRL For RHB-103 (RTTNews)
27.02.14	Salix Pharma, RedHill Biopharma Ink Exclusive License Deal - Quick Facts (RTTNews)
03.02.14	Forest Labs Fights Back, VNDA Gets Thumbs Up From FDA, IntelGenx Awaits Decision (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	51.86	1.25 %	K V
Swiss Life Hldg	773.00	1.18 %	K V
Lonza Grp	601.80	1.07 %	K V
UBS Group	30.43	0.83 %	K V
Zurich Insur Gr	567.80	0.78 %	K V
Logitech Intl	94.18	-0.19 %	K V
Givaudan	4’042.00	-0.42 %	K V
Sika	240.20	-0.78 %	K V
Swisscom	495.80	-0.80 %	K V
Sonova Hldg	299.00	-1.19 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Redhill Biopharma Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten